Evolus (EOLS) IPO Opens Down 6%

Today's IPO for Evolus (NASDAQ: EOLS) opened for trading at $11.25 after pricing 5,000,000 shares of common stock at an initial public offering price of $12.

Evolus has also granted the underwriters a 30-day option to purchase an additional 750,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Evolus.

Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. and JMP Securities LLC are acting as lead managers.

Evolus is a medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. Evolus focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex.

You May Also Be Interested In

• Doncasters (DPC) indicating open around $40, IPO priced at $33
• ChainOn Group files for IPO on Nasdaq at $4-$6 per share
• Doncasters prices IPO at $33 per share on NYSE